FindTrial
Sign In

A study to determine safety and effectiveness of Syrup Urophyll in patients of chronic kidney disease.

A single arm, prospective study to determine safety and efficacy of Syrup Urophyll, 10 ml three times a day in patients diagnosed with chronic kidney disease and not on dialysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/06/008870
Enrollment
33
Registered
2017-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Kidney Disease

Interventions

Intervention1: Syrup Urophyll: Route: Oral Dose: 10 ml thrice a day, diluted with water. Duration: 3 months Intervention2: Syrup Urophyll: Syrup Urophyll is an approved and marketed adjuvant and an a

Sponsors

Thinq Pharma CRO Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Known case of chronic kidney disease aged between 18 and 70 years 2. Written informed consent 3. Serum Creatinine is at least 1.8 mg/dL at the time of screening 4. Blood pressure and blood sugar that is well controlled in the last one year

Exclusion criteria

Exclusion criteria: 1. Patients who has had episode(s) of dialysis in last 6 months 2. History of kidney transplant 3. Pregnant or breast-feeding woman 4. Nephrotic syndrome 5. Patients with uncontrolled diabetes, hypertension, gout or other illness 6. Participant of other clinical trial

Design outcomes

Primary

MeasureTime frame
Serum CreatinineTimepoint: 2 and 3 months post enrollment—

Secondary

MeasureTime frame
Sr. Urea, Hemoglobin, Quality of LifeTimepoint: 2 and 3 months post enrollment—

Countries

India

Contacts

Public ContactDr Sharvari Rangnekar

Quest Clinical Services

dr.rangnekarsharvari@gmail.com9890229919

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026